

PharmaMar receives ISO 14001 and OHSAS 18001 certifications from Lloyds Register Quality Assurance, both international standards for *environmental & occupational health and safety management systems*

- *With these International standard certifications PharmaMar accredits its environmental compromise and its commitment to the safety and health of their workers, and prove the interest of the Group in the implementation of policies and practices to promote continuous improvement and the conservation of the marine environment*
- *Santiago Carrete, of Lloyds Register Quality Assurance delivered the diploma of certification to Luis Mora, CEO of PharmaMar*
- *"These certifications reflect our commitment to the continuous improvement of our environmental management system and will enable us to continue contributing to the knowledge of the marine environment around the world, minimizing the impact on our processes and ensuring the health of our workers," said Luis Rupérez, Director of Human Resources of PharmaMar*
- *PharmaMar is a pioneer company of the biotech sector, where the number of companies certified by the two standards is very low*

Madrid, 27 January 2009: PharmaMar has received ISO 14001 and OHSAS 18001 certifications from Lloyds Register Quality Assurance, both international standards for environmental & occupational health and safety management systems. Santiago Carrete certifications responsible for LRQA has delivered the certification diploma of approval to Luis Mora, PharmaMar General Manager, along with Luis Ruperez, Human Resources Director, Andres Sanz, Head of Environmental and Safety Management Systems, Pedro Berbil, Operations Director and, Jose Luis Ortega, Director of the Quality Unit.

Lloyds Register Quality Assurance (LRQA) has certified that PharmaMar procedures ensure the continuous improvement in its operations, a socially responsible attitude towards the environment, a decrease in consumption and direct or indirect waste generation, (ISO 14001) and a commitment to employees health and to the prevention of occupational hazards (OHSAS 18001).

The implementation of the Safety and Environmental Management standard started in 2004 when the first sustainability reports of the company were issued. The current certification process has lasted 6 months.

"These certifications reflect our commitment to the continuous improvement of our environmental management system and will enable us to continue contributing to the knowledge of the marine environment around the world, minimize the impact on our processes and ensure the health of our workers," said Luis Rupérez, Director of Human Resources of PharmaMar

These certifications prove the interest of the Group in the implementation of policies and practices to promote continuous improvement and the conservation of the marine environment. PharmaMar is a pioneer company of the biotech sector, where the number of companies certified by the two standards is very low.

PharmaMar

PharmaMar is the world-leading biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. Yondelis® is the first Spanish antitumoral compound, currently marketed in the European Union for the treatment of soft tissue sarcomas in adults after the failure of standard therapy. Last December 4th, 2008 PharmaMar submitted a Registration Dossier of Yondelis® in relapsed ovarian cancer (ROC) to the EMEA. A decision on the approval for this indication is expected to take place by mid-2009. PharmaMar has four novel compounds in clinical development: Yondelis® is also in Phase II studies in prostate, breast and pediatric cancers. Aplidin®, Zalypsis®, and Irvalec® are new marine-derived agents in clinical development. PharmaMar also has an extensive portfolio of products in preclinical research and a sound R&D program.

For further information:

Media Relations (Ph: +34 91 846 60 00)

Fernando Mugarza
Carlos Martínez de la Serna
Carolina Lanzas Otazu

Capital Markets (Ph: +34 91 444 45 00)

Alfonso Hurtado de Mendoza
Florencia Radizza

This press release is also available in the News Area of www.pharmamar.com